205 related articles for article (PubMed ID: 36394590)
21. M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
Falleni M; Savi F; Tosi D; Agape E; Cerri A; Moneghini L; Bulfamante GP
Melanoma Res; 2017 Jun; 27(3):200-210. PubMed ID: 28272106
[TBL] [Abstract][Full Text] [Related]
22. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
23. Targeting tumor-associated macrophages as an antitumor strategy.
Cheng N; Bai X; Shu Y; Ahmad O; Shen P
Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
[TBL] [Abstract][Full Text] [Related]
24. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
26. Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors.
Musick M; Yu X
Immunol Res; 2022 Aug; 70(4):432-440. PubMed ID: 35486115
[TBL] [Abstract][Full Text] [Related]
27. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM
J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544
[TBL] [Abstract][Full Text] [Related]
28. Macrophage Susceptibility to Emactuzumab (RG7155) Treatment.
Pradel LP; Ooi CH; Romagnoli S; Cannarile MA; Sade H; Rüttinger D; Ries CH
Mol Cancer Ther; 2016 Dec; 15(12):3077-3086. PubMed ID: 27582524
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
30. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer.
Yagi T; Baba Y; Okadome K; Kiyozumi Y; Hiyoshi Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
Eur J Cancer; 2019 Apr; 111():38-49. PubMed ID: 30822683
[TBL] [Abstract][Full Text] [Related]
31. High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination.
Arlt A; von Bonin F; Rehberg T; Perez-Rubio P; Engelmann JC; Limm K; Reinke S; Dullin C; Sun X; Specht R; Maulhardt M; Linke F; Bunt G; Klapper W; Vockerodt M; Wilting J; Pukrop T; Dettmer K; Gronwald W; Oefner PJ; Spang R; Kube D
Mol Oncol; 2020 Mar; 14(3):571-589. PubMed ID: 31825135
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Ribas A; Dummer R; Puzanov I; VanderWalde A; Andtbacka RHI; Michielin O; Olszanski AJ; Malvehy J; Cebon J; Fernandez E; Kirkwood JM; Gajewski TF; Chen L; Gorski KS; Anderson AA; Diede SJ; Lassman ME; Gansert J; Hodi FS; Long GV
Cell; 2017 Sep; 170(6):1109-1119.e10. PubMed ID: 28886381
[TBL] [Abstract][Full Text] [Related]
33. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
34. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies.
Kumari N; Choi SH
J Exp Clin Cancer Res; 2022 Feb; 41(1):68. PubMed ID: 35183252
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
[TBL] [Abstract][Full Text] [Related]
36. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
Gao J; Liang Y; Wang L
Front Immunol; 2022; 13():888713. PubMed ID: 35844605
[TBL] [Abstract][Full Text] [Related]
37. Targeting tumor-associated macrophages in the tumor microenvironment.
Zhou K; Cheng T; Zhan J; Peng X; Zhang Y; Wen J; Chen X; Ying M
Oncol Lett; 2020 Nov; 20(5):234. PubMed ID: 32968456
[TBL] [Abstract][Full Text] [Related]
38. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
39. Talimogene laherparepvec: First in class oncolytic virotherapy.
Conry RM; Westbrook B; McKee S; Norwood TG
Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
[TBL] [Abstract][Full Text] [Related]
40. The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
Salmi S; Siiskonen H; Sironen R; Tyynelä-Korhonen K; Hirschovits-Gerz B; Valkonen M; Auvinen P; Pasonen-Seppänen S
Melanoma Res; 2019 Jun; 29(3):237-247. PubMed ID: 30399061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]